奥当卡替治疗男性骨质疏松的随机对照试验
这项3期双盲随机安慰剂对照24个月研究纳入292例男性骨质疏松患者,评估奥当卡替50mg每周一次的安全性和疗效。与安慰剂相比,奥当卡替提高腰椎、全髋、股骨颈和转子骨密度,降低骨吸收标志物,骨形成标志物降幅较小且随时间回落。因另一项LOFT试验显示卒中风险增加,奥当卡替研发终止。
要点
- 奥当卡替50mg每周一次提高男性骨质疏松患者腰椎骨密度5.6%(vs安慰剂,p<0.01)。
- 奥当卡替降低uNTx/Cr 68%、sCTx 77%、sP1NP 16%、sBSAP 8%,骨形成标志物降幅3个月达峰后回落。
- 因LOFT试验中卒中风险增加,奥当卡替研发已终止。
核心结论
- 奥当卡替可改善男性骨质疏松患者骨密度并持续降低骨吸收,但另一项LOFT试验显示卒中风险增加,导致研发终止。
研究设计与样本
- 3期双盲随机安慰剂对照24个月研究,纳入292例特发性或性腺功能减退所致男性骨质疏松患者,按1:1随机接受每周一次奥当卡替50mg或安慰剂。
- 所有患者每周补充5600 IU维生素D3,并按需补充钙剂(每日≥1200mg)。
- 主要疗效终点为腰椎骨密度较基线的变化(与安慰剂比较)。
主要发现
- 与安慰剂相比,奥当卡替使腰椎、全髋、股骨颈和转子骨密度分别较基线增加5.6%、2.0%、1.7%和2.1%(均p<0.01)。
- 奥当卡替降低uNTx/Cr 68%(p<0.001)、sCTx 77%(p<0.001)、sP1NP 16%(p=0.001)和sBSAP 8%(p=0.019)。
- 组间骨形成标志物降幅在3个月达峰,随后向基线回落。
- 包括心血管事件在内的安全性特征在组间相似。
关键数值与推荐
- 入组标准:特发性或性腺功能减退所致骨质疏松,腰椎或髋部(全髋、股骨颈或转子)骨密度T值≤-2.5至≥-4.0且无既往椎体骨折,或≤-1.5至≥-4.0且有1次既往椎体骨折。
- 主要疗效终点腰椎骨密度较基线变化:奥当卡替组较安慰剂组增加5.6%(p<0.01)。
临床怎么用
- 奥当卡替虽在男性骨质疏松中显示骨密度提升和骨吸收降低,但因LOFT试验卒中风险增加而终止研发,未进入临床使用。
局限性
- 研究未报告样本量、P值等具体数值以外的局限性信息,原文未涉及其他局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Odanacatib (ODN) was investigated as an osteoporosis treatment in 292 men. Compared with placebo, odanacatib improved bone mineral density and led to sustained bone resorption decreases while producing relatively little bone formation reduction that leveled off with time. However, increased risk of stroke in another study stopped further odanacatib development. INTRODUCTION: ODN, a selective oral cathepsin K inhibitor, was in development for osteoporosis treatment. This phase 3, double-blind, randomized, placebo-controlled, 24-month study investigated ODN safety and efficacy in men with osteoporosis. METHODS: Men with idiopathic osteoporosis or osteoporosis due to hypogonadism and a lumbar spine or hip (total hip [TH], femoral neck [FN], or trochanter) bone mineral density (BMD) T-score of ≤ - 2.5 to ≥ - 4.0 without prior vertebral fracture or ≤ - 1.5 to ≥ - 4.0 with one prior vertebral fracture were randomized (1:1) to once-weekly ODN 50 mg or placebo. All received 5600 IU vitamin D3 weekly and calcium supplementation as needed (≥ 1200 mg daily). The primary efficacy outcome was changed from baseline in lumbar spine BMD versus placebo. RESULTS: Overall, 292 men, mean age 68.8 years, were randomly assigned to ODN or placebo. Versus placebo, ODN increased BMD from baseline at the lumbar spine, TH, FN, and trochanter by 5.6%, 2.0%, 1.7%, and 2.1%, respectively (all p < 0.01), and decreased uNTx/Cr (68%, p < 0.001), sCTx (77%, p < 0.001), sP1NP (16%, p = 0.001), and sBSAP (8%, p = 0.019). The between-group bone formation marker decrease peaked at 3 months, then returned toward baseline. The safety profile, including cardiovascular events, was similar between groups. CONCLUSION: Though a promising osteoporosis therapy for men, ODN development was discontinued due to increased risk of stroke in the LOFT phase 3 trial. TRIAL REGISTRATION: Clinicaltrials.gov NCT01120600 (registered May 11, 2010).
引用
- Binkley N, Orwoll E, Chapurlat R, et al. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporos Int. 2020. PMID: 33200257. doi:10.1007/s00198-020-05701-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。